Axonics to Report Third Quarter 2023 Financial Results on October 30

2 years ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the…

Mark Cuban Cost Plus Drug Company, PBC Joins Forces with Famlee to Revolutionize Access to Home-Based Step-Therapy Fertility Treatment, Providing an Affordable Path to Parenthood

2 years ago

PORTLAND, OR / ACCESSWIRE / October 2, 2023 / Famlee is revolutionizing the landscape of affordable and accessible women's fertility…

Supporting Indigenous Communities: LifeLabs’ Efforts to Provide Health Equity on National Day of Truth and Reconciliation

2 years ago

Marianne McRae, LifeLabs Mobile Laboratory Assistant Marianne McRae, Mobile Laboratory Assistant visiting Qualicum First Nations clinicToronto, Ontario, Sept. 30, 2023…

SmileDirectClub Seeks to Execute Comprehensive Recapitalization to Strengthen the Business for Sustainable Growth

2 years ago

Company Intends to Maintain Normal Operations, Transforming Smiles Without DisruptionNASHVILLE, Tenn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq:…

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2 years ago

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) --  Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

2 years ago

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming…

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to November 3, 2023

2 years ago

MIAMI, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose…

Interim results for the six months ended 30 June 2023

2 years ago

29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa…

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

2 years ago

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a…